The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | ANCHOR: melphalan flufenamide in R/R myeloma
Roman Hajek, MD, PhD, University Hospital Ostrava, Ostrava, Czech Republic, summarizes the Phase II ANCHOR trial (NCT03481556), which investigated melphalan flufenamide (melflufen), a peptide-drug conjugate (PDC), and dexamethasone with either bortezomib or daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. In a group of pretreated patients, the optimal dose of melflufen was determined to be 30 mg and no dose-related toxicities were observed. Recruitment is currently ongoing and additional data will be presented in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
